Garmin Ltd. vs Merck & Co., Inc. — how do they compare? Garmin Ltd. trades at $307.88 (market cap $59.72B), while Merck & Co., Inc. trades at $132.09 (market cap $321.77B). The key difference: Merck & Co., Inc. is far larger — about 5.4× Garmin Ltd.'s market cap, and Merck & Co., Inc. pays the higher dividend (2.61%). Which is the better fit depends on your goals.
| GRMN | MRK | |
|---|---|---|
Market Cap | $59.72B | $321.77B |
Sector | Technology | Health |
52-Week High | $313.16 | $131.84 |
52-Week Low | $187.10 | $77.60 |
Enterprise Value | $57.23B | $368.53B |
Dividend Yield | 1.36% | 2.61% |
Signals from Pluang's Aura AI — not financial advice
Garmin (GRMN) trades at $313.16, up 0.73% on the day and near its all-time high, with a bullish technical trend and strong support at $309. The company reported three consecutive quarterly earnings beats, with Q2 2026 EPS of $2.81 beating estimates of $2.30, and raised full-year guidance. Revenue growth accelerated to 11% in Q2 2026, driven by strong performance in the fitness segment, while net income margin improved to 24.47%.
The outlook remains positive given robust fundamentals and raised guidance, but risks include rich valuation multiples, potential growth deceleration, and insider selling. Analyst consensus is cautious with a hold-heavy rating, though the average price target of $318.67 suggests modest upside from current levels.
Merck (MRK) trades at $130.9, up 1.81% today, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $140.36. Recent earnings beats and a 72.97% gross margin highlight strong profitability, while the acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline. The stock faces headwinds from a high P/E ratio of 104.34 and fluctuating cash flows.
The outlook is positive with robust fundamentals and strategic M&A, but valuation concerns and competitive pressures in pharma pose risks. Upside is likely if earnings growth continues, though investors should monitor debt levels and integration of acquisitions.
Trailing returns across standard periods
Latest headlines on both assets
Garmin produces GPS-enabled hardware and software for five verticals: fitness, outdoors, auto, aviation, and marine. The company relies on licensing mapping data to enable its hardware specialized for often niche activities like scuba diving or sailing. Garmin operates in 100 countries and sells its products via distributors as well as relationships with original equipment manufacturers.
Read more on GRMN →Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →